<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7281404\results\search\testTrace\results.xml">
  <result pre="acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus" exact="infection" post="that causes COVID-19, and it first appeared in Wuhan,"/>
  <result pre="established consensus on the standard of care in the pharmacological" exact="treatment" post="of COVID-19 patients. However, certain medications suggested for other"/>
  <result pre="the better recognition of the virus structure and the quicker" exact="screening" post="of chemical libraries to suggest potential therapies. This review"/>
  <result pre="countries and territories around the world. The agent causing the" exact="infection" post="was rapidly detected to be a beta coronavirus, first"/>
  <result pre="be interpreted with caution. In countries that have implemented massive" exact="screening" post="for the whole population, like South Korea, the overall"/>
  <result pre="to a deranged immune response or a â€œcytokine storm,â€� the" exact="treatment" post="of which may involve immunomodulators. This review covers the"/>
  <result pre="potential agents under investigation in registered clinical trials for the" exact="treatment" post="of COVID-19. Broadly, they are either repurposed antiviral, other"/>
  <result pre="its mutations. An important approach to drug discovery is the" exact="screening" post="of chemical libraries, including a large number of available"/>
  <result pre="against by the FDA (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-seller-marketing-dangerous-chlorine-dioxide-products-claim). The broad strategies for COVID-19" exact="treatment" post="include the targeting of key enzymes of SARS-CoV-2, thus"/>
  <result pre="Several approaches have been suggested to target the current SARS-CoV-2" exact="infection" post="in moderate-to-severe cases in an attempt to control viral"/>
  <result pre="(2) using immunoglobulins and convalescent plasma; and (3) the bioinformatics" exact="screening" post="of chemical libraries for compounds/drugs that are likely to"/>
  <result pre="viral RNA chains. The drug was first developed for the" exact="treatment" post="of Ebola infection [15,16]. It was found to be"/>
  <result pre="The drug was first developed for the treatment of Ebola" exact="infection" post="[15,16]. It was found to be a promising antiviral"/>
  <result pre="prophylactic and therapeutic value of the drug in the MERS-CoV" exact="infection" post="[19]. Another recent in-vitro study reported a half-maximal effective"/>
  <result pre="drugs tested, only remdesivir (and chloroquine) could inhibit the virus" exact="infection" post="in human cells sensitive to SARS-CoV-2 [20]. Recently, on"/>
  <result pre="lopinavir and ritonavir was developed as protease inhibitors for the" exact="treatment" post="of HIV-1 infection. The protease enzyme is an aspartic"/>
  <result pre="Given that success, the combination was recently tried in the" exact="treatment" post="of SARS-CoV-2. In contrast, in a study that included"/>
  <result pre="adult patients admitted to the hospital with severe COVID-19, lopinavir/ritonavir" exact="treatment" post="did not show any benefits compared with the conventional"/>
  <result pre="to compare the combination of darunavir and cobicistat for conventional" exact="treatment" post="in patients with COVID-19 (NCT04252274 and ChiCTR2000029541). 3.1.4. Favipiravir"/>
  <result pre="RNA-dependent RNA polymerase [30]. Favipiravir has been approved for the" exact="treatment" post="of influenza viruses type A and B in a"/>
  <result pre="synthesis of guanosine. The drug is mainly used for the" exact="treatment" post="of viral hepatitis C. It has not shown a"/>
  <result pre="not shown a significant effect as a monotherapy in the" exact="treatment" post="of SARS-CoV or MERS-CoV [31,32]. However, combined with lopinavirâ€&quot;ritonavir"/>
  <result pre="with lopinavir/ritonavir and an interferon-Î± (1a or 1b) in the" exact="treatment" post="of MERS-CoV and showed no significant effect [34,35]. However,"/>
  <result pre="micromolar amounts) used as a model for the new viral" exact="infection" post="of human cells in a study proposed by Klann"/>
  <result pre="and Pharmaceutical Institute. Umifenovir is approved for the prophylaxis and" exact="treatment" post="of human influenza type A and type B infections,"/>
  <result pre="of COVID-19 is investigating the drug as either a single" exact="treatment" post="or in combination with pegylated interferon-Î² atomization for two"/>
  <result pre="oseltamivir alone, in combination with ritonavir, or with ASC09F, in" exact="treatment" post="of COVID-19. ASC09F is an investigational antiviral interferes with"/>
  <result pre="3 (NLRP3) and inflammasome, thus inducing cell pyroptosis in SARS-CoV-2" exact="infection" post="[46]. Tranilast is an antagonist of NLRP3 that inhibits"/>
  <result pre="drug is registered for a Chinese clinical trial in the" exact="treatment" post="of COVID-19 (ChiCTR2000030002). The primary inflammatory responses are usually"/>
  <result pre="decrease in viral load), anti-spike protein-neutralizing antibodies (anti-S-IgG) in SARS-CoV" exact="infection" post="have been found to cause severe lung injury by"/>
  <result pre="2) [48]. A previously described phenomenonâ€&quot;the antibody-dependent enhancement of viral" exact="infection" post="(ADE)â€&quot;may be a plausible explanation. The process of ADE"/>
  <result pre="or other receptors, leading to the exacerbation of target cell" exact="infection" post="[52]. FcR can be blocked by IVIG, thus suppressing"/>
  <result pre="specifically inhibit steps of the viral cycle [57]. Previously, interferon" exact="treatment" post="showed inconclusive activity against SARS-CoV and MERS-CoV. IFNÎ²1 up-regulates"/>
  <result pre="an anti-inflammatory molecule that supports the endothelial barrier. Thus, interferon" exact="treatment" post="reduces vascular leakage in ARDS, [58]. Unfortunately, such an"/>
  <result pre="assumption of COVID-19-associated severe lung injury is that the virus" exact="infection" post="provokes an exaggerated IFN-I-mediated response against the virus, leading"/>
  <result pre="of lopinavir/ritonavir with ribavirin and subcutaneously-administered IFNÃŸ1b (NCT04276688) for the" exact="treatment" post="of COVID-19; see Table 1. 3.2.3. Thymosin-Î±1 In addition"/>
  <result pre="several clinical trials in combination with antiviral agents for the" exact="treatment" post="of COVID-19 (NCT04252274 and ChiCTR2000029541). 4. Immuno-Modulatory Agents 4.1."/>
  <result pre="transcription [64,65]. Baricitinib is reported to be effective in the" exact="treatment" post="of rheumatoid arthritis in several clinical trials [65], with"/>
  <result pre="used together to identify drugs that may halt the viral" exact="infection" post="process. Baricitinib was expected to have a high binding"/>
  <result pre="in China, the drug has received conditional approval for the" exact="treatment" post="of relapsed or refractory Hodgkinâ€™s lymphoma. Camrelizumab is also"/>
  <result pre="determine the effectiveness of PD-1 inhibitors in 2019 novel coronavirus" exact="infection" post="in patients with serious lymphocytopenia-associated pneumonia. On the other"/>
  <result pre="complement activation controls the systemic pro-inflammatory response against the viral" exact="infection" post="[84,85]. Accordingly, eculizumab is expected to stop immune-mediated death"/>
  <result pre="clinical trials for its effectiveness in patients with confirmed COVID-19" exact="infection" post="who are in ICU due to ARDS (NCT04288713). 4.5."/>
  <result pre="was evaluated for its effectiveness and safety as an add-on" exact="treatment" post="in patients with COVID-19 pneumonia. Meplazumab was found to"/>
  <result pre="up the recovery of patients with pneumonia associated with COVID-19" exact="infection" post="with a favorable safety profile [87]. The findings of"/>
  <result pre="out of a large-scale investigation of meplazumab as a possible" exact="treatment" post="for COVID-19 pneumonia. 4.6. Tocilizumab Tocilizumab is a humanized"/>
  <result pre="proliferation and differentiation. The drug is already approved for the" exact="treatment" post="of serious or life-threatening cytokine release syndrome (CRS). The"/>
  <result pre="closely monitored for the emergence of signs and symptoms of" exact="infection" post="during and after treatment with tocilizumab, including the potential"/>
  <result pre="emergence of signs and symptoms of infection during and after" exact="treatment" post="with tocilizumab, including the potential development of tuberculosis in"/>
  <result pre="tuberculosis in patients who have tested negative for latent tuberculosis" exact="infection" post="before starting therapy. Many patients who acquired these infections"/>
  <result pre="the significant exudation of the pulmonary mucus, more evident than" exact="infection" post="with SARS [96]. Pulmonary CT scanning and pathological observation"/>
  <result pre="COVID-19 [97]. Evidence has suggested that bevacizumab is a promising" exact="treatment" post="for critically ill COVID-19 patients. Currently, the drug is"/>
  <result pre="and/or worsen hypertension [98]. Thus, blood pressure monitoring during bevacizumab" exact="treatment" post="and regularly after discontinuation is recommended. 4.9. Fingolimod Fingolimod"/>
  <result pre="COVID-19. Patients with diabetes may get macular edema upon fingolimod" exact="treatment" post="[100]. A clinical trial has been registered to use"/>
  <result pre="of 0.5 mg daily for three consecutive days in the" exact="treatment" post="of severe COVID-19 infection (NCT04280588). 5. Other Anti-Infective Agents"/>
  <result pre="for three consecutive days in the treatment of severe COVID-19" exact="infection" post="(NCT04280588). 5. Other Anti-Infective Agents Repurposed to Treat COVID-19"/>
  <result pre="virus (WNV) infection, Japanese encephalitis virus (JEV), and Zika virus" exact="infection" post="[105]. Those specific viral replication steps depend on the"/>
  <result pre="First, both CQ and HCQ have been used for the" exact="treatment" post="and prophylaxis of malaria and rheumatic diseases for more"/>
  <result pre="or chloroquine have been limited, and their role in COVID-19" exact="treatment" post="is still to be elucidated. Recent reports have found"/>
  <result pre="endorsed an emergency use authorization to permit CQ and HCQ" exact="treatment" post="for hospitalized patients for COVID-19 [109]. There is a"/>
  <result pre="at day six compared to patients who received no specific" exact="treatment" post="(70% versus 12.5%, respectively) [111]. In this study, the"/>
  <result pre="is the first macrolide proved to have efficacy in the" exact="treatment" post="of rhinovirus and influenza virus [118]. On the other"/>
  <result pre="block influenza virus endocytosis into host cells [119]. Regarding macrolide" exact="treatment" post="for COVID-19, Gautret et al. hypothesized that hydroxychloroquine, in"/>
  <result pre="that hydroxychloroquine, in addition to azithromycin, might be an effective" exact="treatment" post="for COVID-19. The mechanism of azithromycin against SARS-CoV-2 is"/>
  <result pre="II receptor blocker (ARB) are two related categories of antihypertensive" exact="treatment" post="that are extensively used to treat hypertension and other"/>
  <result pre="epithelial cell surface [126,129]. Therefore, it has been suggested that" exact="treatment" post="with ACEi or ARB could have a higher expression"/>
  <result pre="ARB via increasing the ACE2 levels and opposing the SARS-CoV-2" exact="infection" post="consequences. Losartan is an AT1R blocker that is widely"/>
  <result pre="in targeting COVID-19 without developing exacerbated hypotension. Another approach for" exact="treatment" post="of COVID-19 is to use a soluble form of"/>
  <result pre="small clinical trial of rhACE2 in patients with severe SARS-CoV-2" exact="infection" post="was recently initiated (NCT04287686). Logically, low cellular membrane ACE2"/>
  <result pre="These opposing effects of ACE2 and, hence, ACEi/ARB or rhACE2," exact="treatment" post="in SARS-CoV-2 infection need more investigation. 6.2. Camostat In-vitro"/>
  <result pre="of ACE2 and, hence, ACEi/ARB or rhACE2, treatment in SARS-CoV-2" exact="infection" post="need more investigation. 6.2. Camostat In-vitro studies have shown"/>
  <result pre="pancreatitis in animal models and has been used for the" exact="treatment" post="of chronic pancreatitis patients in Japan [141]. Therefore, camostat"/>
  <result pre="of critically ill adults with coronavirus diseaseIntensive Care Med.202010.1007/s00134-020-06022-5 7.ContiniA.Virtual" exact="screening" post="of an FDA approved drugs database on two COVID-19"/>
  <result pre="syndrome coronavirusJ. Biol. Chem.20202954772477910.1074/jbc.AC120.013056 19.De WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc. Natl."/>
  <result pre="23.ChanJ.F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.et al.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ. Infect."/>
  <result pre="model of common marmosetJ. Infect. Dis.20152121904191310.1093/infdis/jiv39226198719 24.OldfieldV.PloskerG.L.Lopinavir/ritonavirDrugs2006661275129910.2165/00003495-200666090-0001216827606 25.ChandwaniA.ShuterJ.Lopinavir/ritonavir in the" exact="treatment" post="of HIV-1 infection: A reviewTher. Clin. Risk Manag.200841023103319209283 26.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et"/>
  <result pre="KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 33.ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.et al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findingsThorax20045925225610.1136/thorax.2003.01265814985565 34.Al-TawfiqJ.A.MomattinH.DibJ.MemishZ.A.Ribavirin and"/>
  <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
  <result pre="Sci. USA200299138491385410.1073/pnas.21251969912368467 42.DaviesB.E.Pharmacokinetics of oseltamivir: An oral antiviral for the" exact="treatment" post="and prophylaxis of influenza in diverse populationsJ. Antimicrob. Chemother.201065ii5ii1010.1093/jac/dkq01520215135"/>
  <result pre="and septic shockJ. Intensive Care20131410.1186/2052-0492-1-425705399 55.LauplandK.B.KirkpatrickA.W.DelaneyA.Polyclonal intravenous immunoglobulin for the" exact="treatment" post="of severe sepsis and septic shock in critically ill"/>
  <result pre="Lung Transplant.20203940540710.1016/j.healun.2020.03.012 61.ZhangW.ZhaoY.ZhangF.WangQ.LiT.LiuZ.WangJ.QinY.ZhangX.YanX.et al.The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): The"/>
  <result pre="understanding the safety and efficacy of Janus kinase inhibitors for" exact="treatment" post="of rheumatoid arthritisExpert Rev. Clin. Immunol.2016121047105710.1080/1744666X.2016.118982627253519 65.KoumakiD.KoumakiV.LagoudakiE.BertsiasG.Palmoplantar pustulosis-like eruption"/>
  <result pre="Rev. Clin. Immunol.2016121047105710.1080/1744666X.2016.118982627253519 65.KoumakiD.KoumakiV.LagoudakiE.BertsiasG.Palmoplantar pustulosis-like eruption induced by baricitinib for" exact="treatment" post="of rheumatoid arthritisEur. J. Case Rep. Intern. Med.2019700138332015973 66.KunwarS.CollinsC.E.ConstantinescuF.Baricitinib,"/>
  <result pre="Rep. Intern. Med.2019700138332015973 66.KunwarS.CollinsC.E.ConstantinescuF.Baricitinib, a Janus kinase inhibitor, in the" exact="treatment" post="of rheumatoid arthritis: A systematic literature review and meta-analysis"/>
  <result pre="http://www.ncbi.nlm.nih.gov/pubmed/32150360(accessed on 20 April 2020) 97.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.XuZ.ShiL.WangY.ZhangJ.HuangL.et al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet202039556557432007145 98.TotzeckM.MincuR.I.RassafT.Cardiovascular adverse events in"/>
  <result pre="Scler. Relat. Disord.2013225625810.1016/j.msard.2012.11.00425877733 101.LeeS.J.SilvermanE.BargmanJ.M.The role of antimalarial agents in the" exact="treatment" post="of SLE and lupus nephritisNat. Rev. Nephrol.2011771872910.1038/nrneph.2011.15022009248 102.TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of"/>
  <result pre="cellsScientificWorldJournal2013201328273410.1155/2013/28273423431254 105.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an endocytosis blocking agent, inhibits zika virus" exact="infection" post="in different cell modelsViruses2016832210.3390/v8120322 106.JangC.H.ChoiJ.H.ByunM.S.JueD.M.Chloroquine inhibits production of TNF-alpha,"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
  <result pre="Dis. Soc. Am.202010.1093/cid/ciaa237 109.JieZ.HeH.XiH.ZhiZ.Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumoniaChin. J. Tuberc. Respir. Dis.202043185188 110.collab:"/>
  <result pre="on 20 April 2020) 111.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
  <result pre="al.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1) pdm09 virus" exact="infection" post="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 120.MadridP.B.PanchalR.G.WarrenT.K.ShurtleffA.C.EndsleyA.N.GreenC.E.KolokoltsovA.DaveyR.MangerI.D.GilfillanL.et al.Evaluation"/>
  <result pre="for the clinicianPostgrad. Med.201712949349910.1080/00325481.2017.128567728116959 124.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin protects against zika virus" exact="infection" post="by upregulating virus-induced type I and III interferon responsesAntimicrob."/>
  <result pre="blocked by a clinically proven protease inhibitorCell2020181271280.e810.1016/j.cell.2020.02.05232142651 139.KawaseM.ShiratoK.Van der HoekL.TaguchiF.MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="The primary pathway occurs as an early response to viral" exact="infection" post="before the development of neutralizing antibodies (NAb). The secondary"/>
  <result pre="the presence or suspicion of active and untreated systemic bacterial" exact="infection" post="allergy Minor drug interactions may exist https://clinicaltrials.gov/ct2/show/NCT04346797https://clinicaltrials.gov/ct2/show/NCT04355494https://clinicaltrials.gov/ct2/show/NCT04288713 Meplazumab Anti-CD147"/>
 </snippets>
</snippetsTree>
